Oral acyclovir is extremely useful in managing HSV infections in HIV-infected patients. In the immunocompetent HIV-infected patient, either intermittent or chronic suppressive therapy may be used. The immunosuppressed patient with chronic ulcerative lesions should receive acyclovir (200 to 400 mg orally 5 times daily) until the ulcers heal, which may take several weeks. Then, chronic suppressive therapy should be instituted with acyclovir (400 mg orally twice daily) to reduce recurrences. The newer acyclovir analog antiviral agents are available with better absorption and higher bioavailability. Famciclovir (250 mg 3 times daily) and valaciclovir (100 mg twice daily) are alternatives.
Report an adverse event
Aromatase Promotor – Peonia and Glycyrrhiza are both shown to inhibit testosterone synthesis and stimulate aromatase activity. Both may considered as ingredients in teas, tinctures, and topical formulas for AGA. Paeoniflorin, glycyrrhetic acid and glycyrrhizin are all shown to significantly decrease testosterone without significant effects on androstenedione or estradiol.  Epimedium brevicornum and the Icariin it contains may promote aromatase and be one of the mechanisms where by the plant promotes bone growth in osteoporosis.  Styrax perinsiae contains egonol gentiobioside and egonol gentiotrioside credited with promoting aromatase.